homefeedbacksupportlog on 11-Oct-2008 
  Search
 
   
 
  Browse
ALL OF BIOLOGY

Pharmacology & Drug Discovery
Antimicrobial Agents
Cancer Therapeutics
Cardiovascular Pharmacology
Drug Discovery & Design
Endocrine & Metabolic Pharmacology
Gastrointestinal Pharmacology
Genito-Urinary & Reproductive Pharmacology
Immunopharmacology & Hematologic Pharmacology
Molecular Pharmacology
Musculoskeletal & Dermatologic Pharmacology
Neuropharmacology & Psychopharmacology
Pharmacogenomics
Pharmacokinetics & Drug Delivery
Renal Pharmacology
Respiratory Pharmacology
Toxicology
Related Sections
Bioinformatics
Biomacromolecule-Ligand Interactions
Cell Signalling
Cell Signalling & Trafficking Structures
Chemical Biology of the Cell
Directed Molecular Evolution
Genomics
Macromolecular Chemistry
Medical Genetics
Physiogenomics
Protein Chemistry & Proteomics
Small Molecule Chemistry

profile subject selected for My F1000 Biology

Browse > Pharmacology & Drug Discovery > Pharmacokinetics & Drug Delivery
Top 10 / All time Top 10 / Most viewed / Hidden jewels		Page 1 of 16. Select Page: 1 2 3 4 5 6 7 8 9 10 >>
Display 10 / 20 / 50 papers per page

printer friendly 
to email [Help]

Must Read
F1000 Factor 6.0

New Finding
 Evidence that the anticarcinogenic effect of caffeic acid phenethyl ester in the resistant hepatocyte model involves modifications of cytochrome P450.
Beltrán-Ramírez O, Alemán-Lazarini L, …, Sierra-Santoyo A, Villa-Treviño S
Toxicol Sci 2008 Jul 104(1):100-6 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Howard Glauert
Evaluated 7 Oct 2008

Recommended
F1000 Factor 3.0

Hypothesis
Tech Advance
 Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification.
Maeder ML, Thibodeau-Beganny S, …, Voytas DF, Joung JK
Mol Cell 2008 Jul 25 31(2):294-301 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Brian Kuhlman
Evaluated 3 Oct 2008

Recommended
F1000 Factor 3.0

New Finding
 A domino effect in antifolate drug action in Escherichia coli.
Kwon YK, Lu W, …, Bognar A, Rabinowitz JD
Nat Chem Biol 2008 Oct 4(10):602-8 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Ruma Banerjee
Evaluated 3 Oct 2008

Recommended
F1000 Factor 3.0

Hypothesis
New Finding
 Intracellular protein delivery activity of peptides derived from insulin-like growth factor binding proteins 3 and 5.
Goda N, Tenno T, …, Tanaka T, Hiroaki H
Exp Cell Res 2008 Aug 1 314(13):2352-61 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Steven A. Rosenzweig
Evaluated 1 Oct 2008

Recommended
F1000 Factor 3.0

Confirmation
Controversial
Refutation
 Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.
Obach RS, Kalgutkar AS, Soglia JR, Zhao SX
Chem Res Toxicol 2008 Sep 21(9):1814-22 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Bruce Car
Evaluated 29 Sep 2008

Recommended
F1000 Factor 3.0

New Finding
 Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers.
Kim Y, Hechler B, …, Gachet C, Jacobson KA
Bioconjug Chem 2008 Feb 19(2):406-11 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Donald A. Tomalia
Evaluated 25 Sep 2008

Recommended
F1000 Factor 3.0

Confirmation
Controversial
 Sustained Release of Drugs Dispersed in Polymer Nanoparticles.
Jacobson GB, Shinde R, Contag CH, Zare RN
Angew Chem Int Ed Engl 2008 Sep 4 [abstract on PubMed] [related articles] [full text]
Selected by | Ben Davis
Evaluated 24 Sep 2008

Recommended
F1000 Factor 3.0

Tech Advance
 Colon targeted delivery systems of metronidazole based on osmotic technology: development and evaluation.
Kumar P, Singh S, Mishra B
Chem Pharm Bull (Tokyo) 2008 Sep 56(9):1234-42 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Jacqueline Upcroft
Evaluated 19 Sep 2008

Recommended
F1000 Factor 3.0

Hypothesis
New Finding
Novel Drug Target
 A Novel Delta Opioid Receptor Antagonist, SoRI-9409, Produces a Selective and Long-Lasting Decrease in Ethanol Consumption in Heavy-Drinking Rats.
Nielsen CK, Simms JA, …, Ananthan S, Bartlett SE
Biol Psychiatry 2008 Sep 5 [abstract on PubMed] [related articles] [full text]
Selected by | George Breese with Katie Kelm
Evaluated 17 Sep 2008

Must Read
F1000 Factor 6.0

Tech Advance
Novel Drug Target
 Methanandamide allosterically inhibits in vivo the function of peripheral nicotinic acetylcholine receptors containing the alpha7-subunit.
Baranowska U, Göthert M, Rudz R, Malinowska B
J Pharmacol Exp Ther 2008 Sep 326(3):912-9 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jerry Buccafusco
Evaluated 16 Sep 2008


top of pagePage 1 of 16. Select Page: 1 2 3 4 5 6 7 8 9 10 >>
Display 10 / 20 / 50 papers per page

© 1999-2008 Biology Reports Ltd unless otherwise stated < info@f1000.com >   Terms and conditions   Legal info